# Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma

> **NCT00469417** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 120 (actual)

## Conditions studied

- Superficial Basal Cell Carcinoma

## Interventions

- **DRUG:** Metvix® cream
- **PROCEDURE:** Hand held liquid nitrogen spray cryotherapy

## Key facts

- **NCT ID:** NCT00469417
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-10-18
- **Primary completion:** 2001-09-05
- **Final completion:** 2005-04
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00469417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00469417, "Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00469417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*